QBT-006

QBT-006 is an investigational small molecule ileal bile acid transporter (IBAT) inhibitor developed by Shandong Qingbaixinda Pharmaceutical Technology. It is designed for the treatment of rare cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome. By inhibiting the IBAT protein (also known as SLC10A2) located in the terminal ileum, QBT-006 blocks the reabsorption of bile acids into the enterohepatic circulation. This mechanism promotes the fecal excretion of bile acids, thereby reducing the systemic and intrahepatic bile acid pool. The reduction of bile acid levels is intended to alleviate severe pruritus and prevent progressive liver damage associated with cholestasis. QBT-006 is currently in early-phase clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers and patients.